GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AV-101 overview

AV-101 is under development for the treatment of neuropathic pain, dyskinesia associated with levodopa therapy for Parkinson’s disease, major depressive disorder and suicidal ideation, epilepsy. The drug candidate is administered orally as a capsule. AV-101 is a pro-drug that is converted in the brain into an active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA). It acts by targeting NMDA receptors and AMPA receptors. It was under development for treatment resistant depression and Huntington's disease.

VistaGen Therapeutics overview

VistaGen Therapeutics (VistaGen) is a clinical stage biopharmaceutical company that develops new generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate receptor glycine B intended to treat the major depressive disorder. Its other pipeline products comprise of PH94B treats social anxiety disorder and PH10 nasal spray treats for major depressive disorder. The company offers its products in the form of sprays and oral. It partners with other healthcare industries for researching and assessing drug effects on cardiac risk. VistaGen is headquartered in South San Francisco, California, the US.

For a complete picture of AV-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.